VISTAGEN THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$51.42 million for the 12-month period ending 2016-03-31, per its 10-K filed 2016-06-24.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2016-06-24
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2014-06-30 was -$4.55M.
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2014-03-31 was -$3.04M, a 116.15% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2013-12-31 was -$489.80K.
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2013-06-30 was -$463.60K.
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$51.42M.
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2015 was -$13.99M.
- VISTAGEN THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2014 was -$4.19M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2016-03-31 | -$51.42M 10-K · filed 2016-06-24 | ||||
| 2015-03-31 | -$13.99M 10-K · filed 2016-06-24 | ||||
| 2014-06-30 | -$4.55M 10-Q · filed 2014-08-12 | -$7.60M derived: sum of 2 quarters · filed 2015-06-29 | -$8.09M derived: sum of 3 quarters · filed 2015-06-29 | ||
| 2014-03-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-29 | -$3.53M derived: sum of 2 quarters · filed 2015-06-29 | -$4.19M 10-K · filed 2015-06-29 | ||
| 2013-12-31 | -$489.80K 10-Q · filed 2014-02-14 | -$1.14M 10-Q · filed 2014-02-14 | |||
| 2013-06-30 | -$463.60K 10-Q · filed 2013-08-14 | $18.38M derived: sum of 2 quarters · filed 2014-08-12 | $2.85M derived: sum of 3 quarters · filed 2014-08-12 | ||
| 2013-03-31 | $18.85M derived: 10-Q 12 month − 10-Q 9 month · filed 2014-08-12 | $3.32M derived: sum of 2 quarters · filed 2014-08-12 | -$463.60K 10-Q · filed 2014-08-12 | -$23.08M 10-K · filed 2014-06-25 | |
| 2012-12-31 | -$15.53M 10-Q · filed 2014-02-14 | -$19.31M 10-Q · filed 2014-02-14 | |||
| 2012-06-30 | -$1.83M 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |